This move is archived. Current quotes and coverage live on the stock page.
Get BLCO alerts:
Bausch + Lomb Corp's stock gained 2.04% in the last trading session, reflecting a positive market response to recent developments.
Bausch + Lomb Corp (BLCO.TO) closed at CA$21.50, marking a notable increase of 2.04% in the last trading session. This rise can be attributed to strategic advancements and promising partnerships that are enhancing the company's outlook in the ophthalmic sector.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.87B
52W high
$25.70
52W low
$19.36
1W change
+5.17%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 1.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.07
+1.0% Upside
Current Price
C$24.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.8%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$29.68
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$26.35 | C$24.45 โ C$28.41 |
| 60 trading days | C$27.97 | C$25.15 โ C$31.10 |
| 90 trading days | C$29.68 | C$26.07 โ C$33.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Bausch + Lomb's strategic initiatives, particularly its involvement with Emmecell, which could position the company favorably in the growing market for innovative eye treatments.
Bausch + Lomb Corp Market Cap Surpasses CA$7.57 Billion
With a market cap of CA$7.57 billion, Bausch + Lomb is positioned as a significant player in the healthcare sector, particularly in ophthalmology.
Bull case
The partnership with Emmecell to advance magnetic cell delivery technology is a major step for Bausch + Lomb. This collaboration could broaden its product offerings and increase its market share in eye treatments.
Bear case
Despite the positive movement, investors should be cautious. The company currently has a negative profit margin, which could impact its long-term financial health and ability to take advantage of new opportunities.
Advertisement
Strategic Partnerships Fuel Growth
Bausch + Lomb's recent investment in Emmecell, a company focused on innovative magnetic cell delivery technologies for ophthalmic diseases, has been a key driver behind the stock's positive performance. This partnership not only enhances Bausch + Lomb's portfolio but also aligns with the growing demand for minimally invasive treatment options in eye care.
Market Response and Investor Sentiment
The market's reaction to Bausch + Lomb's advancements reflects a broader optimism surrounding the healthcare sector, particularly in innovative treatments for eye diseases. Investors are encouraged to monitor the company's developments closely, as successful execution of its strategies could lead to sustained growth.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
